NEWS RELEASE- SOURCE Douglas W. House, SA News Editor
Emerald Health Pharmaceuticals (OTCQX:EMHTF) has completed a Phase 1 clinical trial evaluating single ascending doses of lead candidate EHP-101, an oral formulation of a molecule derived from cannabidiol, in 104 healthy volunteers. It was well-tolerated at all doses. Only mild-to-moderate adverse events were observed, even at the highest doses which were well above the expected therapeutic dose for multiple sclerosis and systemic scleroderma.
COMPANY PROFILE
Emerald Health Therapeutics, Inc. is a pharmaceutical company, which engages in the production and sale of cannabis products. Its products include dried cannabis and cannabis oil, pants and seeds. The company was founded on Jul 31, 2007 and is headquartered in Vancouver, Canada.
Emerald Health Pharmaceuticals (OTCQX:EMHTF) has completed a Phase 1 clinical trial evaluating single ascending doses of lead candidate EHP-101, an oral formulation of a molecule derived from cannabidiol, in 104 healthy volunteers. It was well-tolerated at all doses. Only mild-to-moderate adverse events were observed, even at the highest doses which were well above the expected therapeutic dose for multiple sclerosis and systemic scleroderma.
COMPANY PROFILE
Emerald Health Therapeutics, Inc. is a pharmaceutical company, which engages in the production and sale of cannabis products. Its products include dried cannabis and cannabis oil, pants and seeds. The company was founded on Jul 31, 2007 and is headquartered in Vancouver, Canada.